RT Book, Section A1 Njoku, Jessica C. A2 DiPiro, Joseph T. A2 Talbert, Robert L. A2 Yee, Gary C. A2 Matzke, Gary R. A2 Wells, Barbara G. A2 Posey, L. Michael SR Print(0) ID 1164846604 T1 Influenza T2 Pharmacotherapy: A Pathophysiologic Approach, 10e YR 2017 FD 2017 PB McGraw-Hill Education PP New York, NY SN 9781259587481 LK accesspharmacy.mhmedical.com/content.aspx?aid=1164846604 RD 2024/03/28 AB Content UpdateAugust 15, 2019Baloxavir Approved as Novel Treatment for Influenza: The U.S. Food and Drug Administration approved baloxavir marboxil as a new antiviral treatment for influenza on October 24, 2018. The CDC now recommends baloxavir as one of the four FDA-approved antiviral drugs for treatment of seasonal influenza. Baloxavir is administered as a single dose and works by a novel antiviral mechanism of action on influenza RNA polymerase. It has been shown in randomized controlled trials to be comparable to oseltamivir for reducing duration of flu symptoms and serum viral load when given within 48 hours in cases of uncomplicated influenza. There is not yet sufficient literature on baloxavir’s efficacy or adverse events in patients younger than twelve, pregnant women, or hospitalized patients with more severe disease presentations.